Newron reveals 5 deaths in late-stage schizophrenia program as FDA maintains hold
Newron Pharmaceuticals disclosed five deaths in the late-stage trial of its schizophrenia program as an FDA clinical hold remains in place.
Newron Pharmaceuticals
SIX: NWRN $7.59 CHF
Bresso, Italy-based CNS biopharmaceutical company developing evenamide, a glutamate modulator in Phase 3 for treatment-resistant schizophrenia, and marketing Xadago (safinamide) for Parkinson's disease.
Company Info
Sector:Biopharmaceuticals — Central Nervous System
Headquarters:Bresso, Italy
Founded:1999
Website:www.newron.com/
Upcoming Milestones & Key Dates
2026-H2
clinical
ENIGMA-TRS Phase 3 enrollment completion
2027-H1
clinical
Expected Phase 3 data for evenamide
Clinical Development Pipeline
Evenamide
Target: Glutamate modulatorXadago (safinamide)
Target: MAO-B inhibitorRecent News
Leadership Team
Stefan Weber
Chief Executive Officer